Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 2/20 | 0.56 |
| ▸ | PTPN5 | P54829 | 7/20 | 0.51 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.51 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.51 |
| ▸ | CASP6 | P55212 | 1/20 | 0.51 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.51 |
| ▸ | ACLY | P53396 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 7/20 | 0.46 |
| ▸ | PTPN2 | P17706 | 5/20 | 0.46 |
| ▸ | HSPD1 | P10809 | 3/20 | 0.46 |
| ▸ | HSPE1 | P61604 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | FBP1 | P09467 | 1/20 | 0.45 |
| ▸ | EDNRB | P24530 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8541050 | 0.80 | PIK3CD (0.57) | EDNRAPTPN5PTPN11PTPN1PTPN2 | |
| SCHEMBL8350452 | 0.76 | EDNRA (0.54) | EDNRAPTPN5PTPN11DUSP3CASP6 | |
| SCHEMBL8317574 | 0.74 | PIK3CD (0.54) | EDNRAPTPN5PTPN11PTPN1PTPN2 | |
| SCHEMBL6403182 | 0.73 | EDNRA (0.71) | EDNRAPTPN5PTPN11DUSP3CASP6 | |
| SCHEMBL12336164 | 0.73 | EDNRA (0.51) | EDNRAACLYALDH1A1FBP1EDNRB | |
| SCHEMBL12335463 | 0.73 | KEAP1 (0.60) | EDNRAHTTALDH1A1MAPTEDNRB | |
| SCHEMBL6314173 | 0.72 | ALDH1A1 (0.54) | EDNRAHTTALDH1A1MAPTFBP1 | |
| SCHEMBL7046426 | 0.72 | MEN1 (0.61) | EDNRAPTPN5PTPN11DUSP3CASP6 | |
| SCHEMBL6313638 | 0.72 | EDNRA (1.00) | EDNRATSHR | |
| SCHEMBL4201921 | 0.71 | EDNRA (0.98) | EDNRATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014769-A1 | Use of endothelin receptor antogonists for the treatment of tumour diseases | MERCK PATENT GMBH (DE) | 2005-01-20 | — | — | US | claimed |
| EP-1441721-A2 | USE OF ENDOTHELIN RECEPTOR ANTAGONISTS IN THE TREATMENT OF TUMOUR DISEASES | MERCK PATENT GmbH (DE) | 2004-08-04 | — | — | EP | claimed |
| WO-2003039539-A2 | USE OF ENDOTHELIN RECEPTOR ANTAGONISTS IN THE TREATMENT OF TUMOUR DISEASES | MERCK PATENT GMBH (DE) | 2003-05-15 | — | — | WO | claimed |
| EP-0733626-B1 | N-(Benzofuranazyl)-arylsulphonamides and their analogues useful as endothelin-receptor-antagonists | MERCK PATENT GMBH (DE) | 1999-01-13 | — | — | EP | claimed |
| EP-0733626-A1 | N-(Benzofuranazyl)-arylsulphonamides and their analogues useful as endothelin-receptor-antagonists | MERCK PATENT GmbH (DE) | 1996-09-25 | — | — | EP | claimed |
| US-20050014769-A1 | Use of endothelin receptor antogonists for the treatment of tumour diseases | MERCK PATENT GMBH (DE) | 2005-01-20 | — | — | US | disclosed |
| EP-1441721-A2 | USE OF ENDOTHELIN RECEPTOR ANTAGONISTS IN THE TREATMENT OF TUMOUR DISEASES | MERCK PATENT GmbH (DE) | 2004-08-04 | — | — | EP | disclosed |
| WO-2003039539-A2 | USE OF ENDOTHELIN RECEPTOR ANTAGONISTS IN THE TREATMENT OF TUMOUR DISEASES | MERCK PATENT GMBH (DE) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014769-A1 | Use of endothelin receptor antogonists for the treatment of tumour diseases | EDNRA, EDNRB, ECE1 | EDNRA 1/4885PTPN5 3882/4885PTPN11 2984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.